METOLAZONE tablet

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

METOLAZONE (UNII: TZ7V40X7VX) (METOLAZONE - UNII:TZ7V40X7VX)

Commercializzato da:

Mylan Pharmaceuticals Inc.

INN (Nome Internazionale):

METOLAZONE

Composizione:

METOLAZONE 2.5 mg

Via di somministrazione:

ORAL

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

Metolazone tablets are indicated for the treatment of salt and water retention including: Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox® tablets are to be substituted for Zaroxolyn® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets

Dettagli prodotto:

Metolazone Tablets, USP are available containing 2.5 mg, 5 mg and 10 mg of metolazone, USP. The 2.5 mg tablets are peach, round, biconvex, unscored tablets debossed with M on one side of the tablet and 172 on the other side. They are available as follows: NDC 0378-6172-01 bottles of 100 tablets The 5 mg tablets are orange, round, biconvex, unscored tablets debossed with M on one side of the tablet and 173 on the other side. They are available as follows: NDC 0378-6173-01 bottles of 100 tablets The 10 mg tablets are light green, round, biconvex, unscored tablets debossed with M on one side of the tablet and 174 on the other side. They are available as follows: NDC 0378-6174-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Hyderabad — 500 096, India 75069724 Revised: 10/2019 MX:MTLZ:R1

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

METOLAZONE- METOLAZONE TABLET
MYLAN PHARMACEUTICALS INC.
----------
DO NOT INTERCHANGE: DO NOT INTERCHANGE ZAROXOLYN TABLETS AND
OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS SLOW AND
INCOMPLETE BIOAVAILABILITY AND ARE NOT THERAPEUTICALLY EQUIVALENT
AT THE SAME DOSES TO MYKROX TABLETS, A MORE RAPIDLY AVAILABLE AND
COMPLETELY BIOAVAILABLE METOLAZONE PRODUCT. FORMULATIONS
BIOEQUIVALENT TO ZAROXOLYN AND FORMULATIONS BIOEQUIVALENT TO
MYKROX SHOULD NOT BE INTERCHANGED FOR ONE ANOTHER.
1
2
DESCRIPTION
Metolazone Tablets, USP for oral administration contain 2.5 mg, 5 mg
or 10 mg of metolazone, USP, a
diuretic/saluretic/antihypertensive drug of the quinazoline class.
Metolazone has the molecular formula C
H ClN O S, the chemical name 7-chloro-1, 2, 3, 4-
tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide,
and a molecular weight of
365.83. The structural formula is:
Metolazone is only sparingly soluble in water, but more soluble in
plasma, blood, alkali, and organic
solvents. Inactive Ingredients: colloidal silicon dioxide, FD&C Yellow
#6 Lake HT, magnesium
stearate and microcrystalline cellulose. In addition, the 10 mg
strength contains D&C Yellow #10 Lake
HT and FD&C Blue #2 Lake HT.
_Meets USP Dissolution Test 2._
CLINICAL PHARMACOLOGY
Metolazone is a quinazoline diuretic, with properties generally
similar to the thiazide diuretics. The
actions of metolazone result from interference with the renal tubular
mechanism of electrolyte
reabsorption. Metolazone acts primarily to inhibit sodium reabsorption
at the cortical diluting site and to
a lesser extent in the proximal convoluted tubule. Sodium and chloride
ions are excreted in
approximately equivalent amounts. The increased delivery of sodium to
the distal tubular exchange site
results in increased potassium excretion. Metolazone does not inhibit
carbonic anhydrase. A proximal
action of metolazone has been shown in humans by increased excretion
of phosphate and magnesium
®1
®2
®
®
ZAROXOLYN IS A REG ISTERED TRADEMARK OF CELLTECH PHARMACEUTICALS,